Global Head and Neck Cancer Drug Market is rise gradually to an estimated value of USD 2.59 Billion by 2026 registering a CAGR of 8.1% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing awareness and concerns regarding the health of patients.
The key factors added in this report will help leading players modify their manufacturing and marketing strategies to maximize their business growth in the coming years. Major competitors along with innovative analysis of their current developments, core competencies, product portfolio and investments in each segment are highlighted in the report. On the basis of the application type and geography, the head and neck cancer drug report splits the market size by volume and value. This report also considers the changes and advancements taking place in the global market. This research report will give clear idea to readers about the overall market scenario to further decide on this market project.
Get an Exclusive Sample Report Now https://databridgemarketresearch.com/request-a-sample/?dbmr=global-head-and-neck-cancer-drug-market
According to the published article in American Society of Clinical Oncology in Jan 2019, it is identified that there are 65,410 cases of head and neck cancer, of which 48,000 are men and 17,410 are women. It is estimated that 14,620 patients will be dying from this disease in the current year. This significant rise in patient number acts as a driver for the growth of head and cancer drugs.
Leading major competitors currently working in the Head and neck cancer drug Cancer market are AstraZeneca Plc , Immutep, Fortress Biotech, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck KGaA, Bristol-Myers Squibb Company, Novartis AG, Merck & Co., Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc. and few among others.
Market Drivers
- Increase in prevalence rate of Head and neck cancer worldwide
- Chronic consumption of Tobacco products and alcohol
- Rising awareness about treatment and technological advancement is driving the growth of market
- Increase in the rate of R&D initiatives is driving Head and neck Cancer therapeutics market
Market Restraints
- High cost involved in the treatment
- Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market
- Lack of awareness among the patient and physician about head and neck treatment
Key Developments in the Market:
In September 2018, Regeneron Pharmaceuticals, Inc. received FDA approval of Libtayo (cemiplimab-rwlc) for the treatment of patient with head and neck cancer or advanced squamous cell carcinoma. Libtaya is PD-1 (protein found on the body’s immune cells and some cancer cells) blocking antibody. The recommended dose of LIBTAYO is 350 mg given by intravenous infusion over 30 minutes every 3 weeks.
In April 2019, Merck & Co., Inc. got FDA expanded label approval of KEYTRUDA (pembrolizumab) for the treatment of recurrent or metastatic head and neck squamous cell carcinoma. It is given after the administration of platinum containing chemotherapy. Keytruda is anti PD-1 antibodies that act as immunomodulatory agent.
Know the answer to all your doubts of Head and neck cancer drug Market report@ https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-head-and-neck-cancer-drug-market
Segmentation: Global Head and Neck Cancer Drug Market
By Type
- Laryngeal and hypopharyngeal cancer
- Nasal cavity and paranasal sinus cancer
- Oral and oropharyngeal cancer
- Salivary gland cancer
- Nasopharyngeal cancer
- Others
By Drug Type
- Carboplatin
- Cisplatin
- Docetaxel
- Paclitaxel
- 5-fluorouracil
- Epirubicin
- Immunomodulators
- Others
By Treatment
- Medication
- Chemotherapy
- Radiation therapy
- Immunotherapy
- Targeted Therapy
- Surgery
By Route of administration
- Oral
- Injectable
By End users
- Hospitals
- Homecare
- Specialty Clinics
- Others
By Geography
- North America
- South America
- Europe
- Asia-Pacific
- Middle East & Africa
Avail 25% Instant Discount At https://www.databridgemarketresearch.com/request-a-discount/global-head-and-neck-cancer-drug-market
Market Drivers
- Increase in prevalence rate of Head and neck cancer worldwide
- Chronic consumption of Tobacco products and alcohol
- Rising awareness about treatment and technological advancement is driving the growth of market
- Increase in the rate of R&D initiatives is driving Head and neck Cancer therapeutics market
Table of Contents:
- Executive Summary
- Scope/opportunities of the Report
- Research Methodology
- Market Landscape
- Pipeline Analysis
- Market Sizing
- Porter’s Five Forces Analysis
- Market Segmentation
- Customer Landscape
- Regional Landscape
- Business Decision Framework
- Drivers And Challenges
- Market Key Trends
- Players Landscape
- Players Analysis
- Appendix
Get Detail TOC @ https://databridgemarketresearch.com/toc/?dbmr=global-head-and-neck-cancer-drug-market
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.
Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475